[
  {
    "HGNCID": 341,
    "Gene": "AGXT",
    "Condition/indication": "Primary Hyperoxaluria Type 1",
    "Generic Name": "Lumasiran",
    "Marketed drug": "Oxlumo",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Type": "siRNA",
    "Company": "ALNYLAM PHARMS INC",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB15935"
  },
  {
    "HGNCID": 341,
    "Gene": "AGXT",
    "Condition/indication": "Primary Hyperoxaluria Type 1",
    "Generic Name": "Nedosiran",
    "Marketed drug": "Rivfloza",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Type": "siRNA",
    "Company": "Dicerna Pharmaceuticals, Inc",
    "Market ": "US",
    "DrugBank ID": "DB17635"
  },
  {
    "HGNCID": 2928,
    "Gene": "DMD",
    "Condition/indication": "Duchenne muscular dystrophy",
    "Generic Name": "Eteplirsen",
    "Marketed drug": "Exondys",
    "Modality": "RNA therapy",
    "Mechanism": "exon skipping",
    "Type": "blockmer, PMO",
    "Company": "Sarepta Therapeutics",
    "Market ": "US",
    "DrugBank ID": "DB06014"
  },
  {
    "HGNCID": 2928,
    "Gene": "DMD",
    "Condition/indication": "Duchenne muscular dystrophy",
    "Generic Name": "Golodirsen",
    "Marketed drug": "Vyondys 53",
    "Modality": "RNA therapy",
    "Mechanism": "exon skipping",
    "Type": "blockmer, PMO",
    "Company": "Sarepta Therapeutics",
    "Market ": "US",
    "DrugBank ID": "DB15593"
  },
  {
    "HGNCID": 2928,
    "Gene": "DMD",
    "Condition/indication": "Duchenne muscular dystrophy",
    "Generic Name": "Viltolarsen",
    "Marketed drug": "Viltepso",
    "Modality": "RNA therapy",
    "Mechanism": "exon skipping",
    "Type": "blockmer, PMO",
    "Company": "NIPPON SHINYAKU",
    "Market ": "US",
    "DrugBank ID": "DB15005"
  },
  {
    "HGNCID": 2928,
    "Gene": "DMD",
    "Condition/indication": "Duchenne muscular dystrophy",
    "Generic Name": "Casimersen",
    "Marketed drug": "Amondys 45",
    "Modality": "RNA therapy",
    "Mechanism": "exon skipping",
    "Type": "blockmer, PMO",
    "Company": "Sarepta Therapeutics",
    "Market ": "US",
    "DrugBank ID": "DB14984"
  },
  {
    "HGNCID": 11117,
    "Gene": "SMN1",
    "Condition/indication": "Spinal Muscular Atrophy",
    "Generic Name": "Nusinersen",
    "Marketed drug": "Spinraza",
    "Modality": "RNA therapy",
    "Mechanism": "exon inclusion",
    "Type": "blockmer, full MOE",
    "Company": "Ionis Pharmaceuticals, Inc.",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB13161"
  },
  {
    "HGNCID": 11179,
    "Gene": "SOD1",
    "Condition/indication": "SOD1-associated ALS",
    "Generic Name": "Tofersen",
    "Marketed drug": "Qalsody",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Company": "Biogen",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB14782"
  },
  {
    "HGNCID": 12405,
    "Gene": "TTR ",
    "Condition/indication": "Hereditary Transthyretin-mediated amyloidosis",
    "Generic Name": "Inotersen",
    "Marketed drug": "Tegsedi",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Type": "MOE gapmer",
    "Company": "Ionis Pharmaceuticals, Inc.",
    "Additional Information": "Canada - cancelled post-market",
    "Market ": "US/Canada (cancelled post-market)/EMA",
    "DrugBank ID": "DB14713"
  },
  {
    "HGNCID": 12405,
    "Gene": "TTR ",
    "Condition/indication": "Hereditary Transthyretin-mediated amyloidosis",
    "Generic Name": "Eplontersen",
    "Marketed drug": "Wainua",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Type": "GaNac MOE gapmer",
    "Company": "AstraZeneca and Ionis",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB16199"
  },
  {
    "HGNCID": 12405,
    "Gene": "TTR ",
    "Condition/indication": "Hereditary Transthyretin-mediated amyloidosis",
    "Generic Name": "Patisiran",
    "Marketed drug": "Onpattro",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Type": "siRNA",
    "Company": "ALNYLAM PHARMS INC",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB14582"
  },
  {
    "HGNCID": 12405,
    "Gene": "TTR ",
    "Condition/indication": "Hereditary Transthyretin-mediated amyloidosis",
    "Generic Name": "Vutrisiran",
    "Marketed drug": "Amvuttra",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Type": "siRNA",
    "Company": "ALNYLAM PHARMS INC",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB16699"
  },
  {
    "Gene": "APOB, LDLR, PCSK9",
    "Condition/indication": "Homozygous Familial Hypercholesterolemia",
    "Generic Name": "Mipomersen",
    "Marketed drug": "Kynamro (withdrawn)",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Type": "MOE gapmer",
    "Company": "Genzyme",
    "Additional Information": "withdrawn",
    "Market ": "US",
    "DrugBank ID": "DB05528"
  },
  {
    "Gene": "x",
    "Condition/indication": "Acute Hepatic Porphyria",
    "Generic Name": "Givosiran",
    "Marketed drug": "Givlaari",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Type": "siRNA",
    "Company": "ALNYLAM PHARMS INC",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB15066",
    "Comment ": "multiple enzyme deficiences"
  },
  {
    "Gene": "APOB, LDLR, PCSK9",
    "Condition/indication": "Heterozygous Familial Hyperchloesterolemia",
    "Generic Name": "Inclisiran",
    "Marketed drug": "Leqvio",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Type": "siRNA",
    "Company": "Novartis",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB14901",
    "Comment ": "multiple genetic disorders"
  },
  {
    "HGNCID": 6677,
    "Gene": "LPL",
    "Condition/indication": "Familial Chylomicronemia",
    "Generic Name": "Volanesorsen",
    "Marketed drug": "Waylivra",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Type": "MOE gapmer",
    "Company": "Akcea and Ionis",
    "Market ": "EMA",
    "DrugBank ID": "DB15067"
  },
  {
    "Condition/indication": "myelodysplastic syndrome",
    "Generic Name": "Imetelstat",
    "Marketed drug": "Rytelo",
    "Modality": "RNA therapy",
    "Mechanism": "inhibitor",
    "Type": "ASO",
    "Company": "Geron Corporation",
    "Market ": "US",
    "DrugBank ID": "DB14909",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 6677,
    "Gene": "LPL",
    "Condition/indication": "familial chylomicronemia syndrome (FCS)",
    "Generic Name": "Olezarsen",
    "Marketed drug": "Tryngolza",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Type": "GalNAc ASO",
    "Company": "Ionis Pharmaceuticals, Inc.",
    "Market ": "US",
    "DrugBank ID": "DB18728"
  },
  {
    "Gene": "F8, F9",
    "Condition/indication": "Hemophilia A or B",
    "Generic Name": "Fitusiran",
    "Marketed drug": "Qfitlia",
    "Modality": "RNA therapy",
    "Mechanism": "knockdown",
    "Type": "GalNac siRNA",
    "Company": "ALNYLAM PHARMS INC",
    "Market ": "US",
    "DrugBank ID": "DB15002"
  },
  {
    "Condition/indication": "neovascular (wet) age-related macular degeneration",
    "Generic Name": "Pegaptanib",
    "Marketed drug": "Macugen",
    "Modality": "RNA therapy",
    "Mechanism": "inhibitor",
    "Type": "aptamer",
    "Company": "OSI/Eyetech Pharmaceuticals, New York, NY and Pfizer, New York, NY",
    "Market ": "Withdrawn",
    "DrugBank ID": "DB04895",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "age-related macular degeneration",
    "Generic Name": "Avacincaptad pegol",
    "Marketed drug": "Izervay",
    "Modality": "RNA therapy",
    "Mechanism": "inhibitor",
    "Type": "aptamer",
    "Company": "Astellas Pharma Inc.",
    "Market ": "US",
    "DrugBank ID": "DB15165",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "Relapsed or Refractory Multiple Myeloma",
    "Generic Name": "Idecabtagene vicleucel",
    "Marketed drug": "Abecma™",
    "Modality": "Cell therapy",
    "Mechanism": "Idecabtagene vicleucel / autologous CAR T -cellsyu76h, CAR T cells recognize the B-cell maturation antigen (BCMA) and kill BCMA-expressing tumor cells. A lentiviral vector, developed by bluebird bio, is used to engineer the CAR T cells.",
    "Type": "Ex vivo GTMP",
    "Company": "Celgene",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB16665",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)",
    "Generic Name": "Nadofaragene firadenovec",
    "Marketed drug": "Adstiladrin",
    "Modality": "Gene therapy",
    "Mechanism": "A recombinant adenovirus (rAd-IFNa/Syn3) delivers human interferon alfa-2b cDNA into the bladder epithelium. Treats patients with certain types of bladder cancer.",
    "Type": "Adenovirus",
    "Company": "Ferring Pharmaceuticals",
    "Market ": "US",
    "DrugBank ID": "DB17381",
    "Comment ": "not for rare disease"
  },
  {
    "Generic Name": "cord blood injectable suspension for intravenous use",
    "Marketed drug": "ALLOCORD",
    "Modality": "Cell therapy",
    "Mechanism": "Blood cell transplant derived from umbilical cord and placenta.",
    "Type": "Cell (allogeneic)",
    "Company": "SSM Cardinal Glennon Children's Medical Center",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "Complex perianal fistulas in patients with Crohn’s disease",
    "Generic Name": "Darvadstrocel",
    "Marketed drug": "Alofisel™",
    "Modality": "Cell therapy",
    "Mechanism": "Darvadstrocel / Mesenchymal stem cells from fat tissue of adult donors",
    "Type": "SCTMP",
    "Company": "Takeda Pharma",
    "Additional Information": "withdrawn by EMA",
    "Market ": "N/A",
    "DrugBank ID": "DB16581",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "adult patients with unresectable or metastatic melanoma",
    "Generic Name": "Lifileucel",
    "Marketed drug": "AMTAGVI",
    "Modality": "Cell therapy",
    "Mechanism": "Engineered T cells for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.",
    "Type": "Cell (modified)",
    "Company": "Iovance Biotherapeutics, Inc.",
    "Market ": "US",
    "DrugBank ID": "DB17107",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "acute lymphoblastic leukemia",
    "Generic Name": "Obecabtagene autoleucel",
    "Marketed drug": "AUCATZYL",
    "Modality": "Cell therapy",
    "Company": "Autolus Limited",
    "Market ": "US",
    "DrugBank ID": "DB17362",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 3551,
    "Gene": "F9",
    "Condition/indication": "adults with moderate to severe hemophilia B",
    "Generic Name": "Fidanacogene elaparvovec",
    "Marketed drug": "BEQVEZ",
    "Modality": "Gene therapy",
    "Mechanism": "AAV-mediated gene therapy for the treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid.",
    "Type": "AAVRh74var",
    "Company": "Pfizer, Inc.",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB16783"
  },
  {
    "Condition/indication": "Relapsed or Refractory Large B-cell lymphoma Non-Hodgkin lymphoma Follicular lymphoma",
    "Generic Name": "Lisocabtagene maraleucel",
    "Marketed drug": "Breyanzi",
    "Modality": "Cell therapy",
    "Mechanism": "CAR T cells engineered with lentivirus to attack CD19-expressing tumor cells. Treats patients with certain kinds of large B-cell lymphoma.",
    "Type": "Ex vivo GTMP, Cell (autologous, modified)",
    "Company": "Juno Therapeutics",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB16582",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "Relapsed or Refractory Multiple Myeloma",
    "Generic Name": "Ciltacabtagene autoleucel",
    "Marketed drug": "CARVYKTI",
    "Modality": "Cell therapy",
    "Mechanism": "CAR T cells engineered with lentivirus to attack BCMA-expressing tumor cells. Treats patients with certain kinds of relapsed or refractory multiple myeloma. Ciltacabtagene autoleucel / autologous CAR T cells directed to B cell maturation antigen (BCMA)",
    "Type": "Ex vivo GTMP, Cell (autologous, modified)",
    "Company": "Janssen Biotech, Inc.",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB16738",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 4827,
    "Gene": "HBB",
    "Condition/indication": "sickle cell disease, beta thalassaemia",
    "Generic Name": "Exagamglogene autotemcel",
    "Marketed drug": "Casgevy",
    "Modality": "Cell/Gene therapy",
    "Mechanism": "CD34+ hematopoietic stem cells engineered with electroporation of CRISPR/Cas9 RNP complexes to decrease expression of BCL11A to increase fetal hemoglobin production. Treats patients with certain kinds of sickle cell disease.",
    "Type": "Ex vivo, Cell (autologous, modified)",
    "Company": "Vertex Pharmaceuticals",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB15572"
  },
  {
    "Generic Name": "HPC, Cord Blood",
    "Marketed drug": "CLEVECORD",
    "Modality": "Cell therapy",
    "Mechanism": "Transplant of hematopoietic progenitor cells (HPCs) from human cord blood.",
    "Type": "Cell (allogeneic)",
    "Company": "Cleveland Cord Blood Center",
    "Comment ": "not for rare disease"
  },
  {
    "Generic Name": "HPC, Cord Blood",
    "Marketed drug": "DUCORD",
    "Modality": "Cell therapy",
    "Mechanism": "Transplant of HPCs from human cord blood.",
    "Type": "Cell (allogeneic)",
    "Company": "Duke University School of Medicine",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "Second-line treatment for transplant recipients who develop, as a result of immunosuppression treatment, Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disease (PTLD)",
    "Generic Name": "Tabelecleucel",
    "Marketed drug": "Ebvallo™",
    "Mechanism": "Tabelecleucel / allogeneic, EBV-specific T-cells from matched donor",
    "Type": "SCTMP",
    "Company": "Atara Biotherapeutics",
    "Market ": "US/EMA",
    "DrugBank ID": "DB17072",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 2928,
    "Gene": "DMD",
    "Condition/indication": "Duchenne muscular dystrophy",
    "Generic Name": "Delandistrogene moxeparvovec",
    "Marketed drug": "Elevidys",
    "Modality": "Gene therapy",
    "Mechanism": "Recombinant AAVrh74 delivers a micro-dystrophin gene to treat patients with certain types of Duchenne muscular dystrophy.",
    "Type": "In vivo, AAVrh74",
    "Company": "SAREPTA",
    "Market ": "US",
    "DrugBank ID": "DB16802"
  },
  {
    "Condition/indication": "macular telangiectasia type 2",
    "Generic Name": "Revakinagene taroretcel",
    "Marketed drug": "Encelto",
    "Mechanism": "allogeneic encapsulated cell-based gene therapy used for the treatment of macular telangiectasia type 2",
    "Company": "Neurotech Pharmaceuticals",
    "Market ": "US",
    "DrugBank ID": "DB05344",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "Topical (non-submerged) application to a surgically created vascular wound bed in the treatment of mucogingival conditions in adults (venous leg ulcers)",
    "Generic Name": "Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen",
    "Marketed drug": "GINTUIT",
    "Modality": "Cell therapy",
    "Mechanism": "Cellularized scaffold for topical application to a surgically created wound bed to treat certain mucogingival conditions. Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen",
    "Type": "TEP",
    "Company": "Organogenesis Inc.",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 6677,
    "Gene": "LPL",
    "Condition/indication": "lipoprotein lipase deficiency",
    "Generic Name": "Alipogene tiparvovec",
    "Marketed drug": "Glybera (withdrawn)",
    "Modality": "Gene therapy",
    "Type": "In vivo AAV1",
    "Company": "Chiesi Farmaceutici",
    "Additional Information": "withdrawn",
    "DrugBank ID": "DB13521"
  },
  {
    "Generic Name": "Human cord blood hematopoietic progenitor cell",
    "Marketed drug": "HEMACORD",
    "Modality": "Cell therapy",
    "Mechanism": "Transplant of HPCs from human cord blood.",
    "Type": "Cell (allogeneic)",
    "Company": "New York Blood Center",
    "Market ": "US",
    "DrugBank ID": "DB11054",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 3551,
    "Gene": "F9",
    "Condition/indication": "Adult patients with hemophilia B",
    "Generic Name": "Etranacogene dezaparvovec",
    "Marketed drug": "HEMGENIX",
    "Modality": "Gene therapy",
    "Mechanism": "Recombinant AAV5 delivers F9 to treat patients with certain kinds of Hemophilia B. Etranacogene dezaparvovec / AAV5 vector containing the cDNA of human coagulation factor IX",
    "Type": "In vivo GTMP AAV5",
    "Company": "CSL Behring LLC, UniQure",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB16791"
  },
  {
    "Condition/indication": "Patients with corneal damage due to (chemical) burns",
    "Generic Name": "Ex vivo expanded autologous human corneal epithelial cells containing stem cells",
    "Marketed drug": "Holoclar™",
    "Modality": "Cell therapy",
    "Mechanism": "Ex vivo expanded autologous human corneal epithelial cells containing stem cells",
    "Type": "SCTMP",
    "Company": "Holostem Advanced Therapies",
    "Market ": "EMA",
    "DrugBank ID": "DB18660",
    "Comment ": "not for rare disease"
  },
  {
    "Marketed drug": "HPC, Cord Blood",
    "Modality": "Cell therapy",
    "Mechanism": "Transplant of HPCs from human cord blood.",
    "Type": "Cell (allogeneic)",
    "Company": "Clinimmune Labs, University of Colorado Cord Blood Bank",
    "Comment ": "not for rare disease"
  },
  {
    "Marketed drug": "HPC, Cord Blood - Bloodworks",
    "Modality": "Cell therapy",
    "Mechanism": "Transplant of HPCs from human cord blood.",
    "Type": "Cell (allogeneic)",
    "Company": "Bloodworks",
    "Comment ": "not for rare disease"
  },
  {
    "Marketed drug": "HPC, Cord Blood - LifeSouth",
    "Modality": "Cell therapy",
    "Mechanism": "Transplant of HPCs from human cord blood.",
    "Type": "Cell (allogeneic)",
    "Company": "LifeSouth Community Blood Centers, Inc.",
    "Comment ": "not for rare disease"
  },
  {
    "Marketed drug": "HPC, Cord Blood - MD Anderson Cord Blood Bank",
    "Modality": "Cell therapy",
    "Mechanism": "Transplant of HPCs from human cord blood.",
    "Type": "Cell (allogeneic)",
    "Company": "MD Anderson Cord Blood Bank",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "melanoma",
    "Generic Name": "Talimogene laherparepvec",
    "Marketed drug": "Imlygic",
    "Modality": "Gene therapy",
    "Mechanism": "Recombinant HSV-1 delivers GM-CSF to treat patients with certain unresectable melanoma lesions. Talimogene laherparepvec / HSV-1 oncolytic virus containing the cDNA of human GM-CSF",
    "Type": "In vivo, HSV-1",
    "Company": "Amgen",
    "Market ": "US/EMA",
    "DrugBank ID": "DB13896",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 2719,
    "Gene": "DDC",
    "Condition/indication": "aromatic L‑amino acid decarboxylase (AADC) deficiency",
    "Generic Name": "Eladocagene exuparvovec",
    "Marketed drug": "KEBILIDI (eladocagene exuparvovec-tneq)",
    "Modality": "Gene therapy",
    "Type": "In vivo",
    "Company": "PTC Therapeutics",
    "Market ": "US/EMA",
    "DrugBank ID": "DB16780"
  },
  {
    "Condition/indication": "B cell lymphoblastic leukemia",
    "Generic Name": "Tisagenlecleucel",
    "Marketed drug": "Kymriah",
    "Modality": "Cell therapy",
    "Mechanism": "CAR T cells engineered with lentivirus to attack CD19-expressing tumor cells. Treats patients with certain kinds of relapsed or refractory follicular lymphoma.",
    "Type": "Cell (autologous, modified)",
    "Company": "Novartis",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB13881",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "Acute Lymphoblastic Leukemia (ALL)",
    "Generic Name": "Tisagenlecleucel",
    "Marketed drug": "KYMRIAH",
    "Modality": "Cell therapy",
    "Mechanism": "CAR T cells engineered with lentivirus to attack CD19-expressing tumor cells. Treats patients with certain kinds of relapsed or refractory follicular lymphoma.",
    "Type": "Cell (autologous, modified)",
    "Company": "Novartis Pharmaceuticals Corporation",
    "Comment ": "not for rare disease"
  },
  {
    "Generic Name": "Donislecel",
    "Marketed drug": "LANTIDRA",
    "Modality": "Cell therapy",
    "Mechanism": "Pancreatic islet cells from a deceased donor are transplanted to treat patients with certain types of type I diabetes.",
    "Type": "Cell (allogeneic)",
    "Company": "CellTrans Inc.",
    "Market ": "US",
    "DrugBank ID": "DB17961",
    "Comment ": "not for rare disease"
  },
  {
    "Generic Name": "Azficel-T",
    "Marketed drug": "LAVIV (withdrawn)",
    "Modality": "Cell therapy",
    "Mechanism": "Fibroblasts to improve the appearance of moderate to severe nasolabial fold wrinkles.",
    "Type": "Cell (autologous, expanded)",
    "Company": "Fibrocell Technologies",
    "Market ": "Withdrawn",
    "DrugBank ID": "DB11051",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 713,
    "Gene": "ARSA",
    "Condition/indication": "metachromatic leukodystrophy",
    "Generic Name": "Atidarsagene autotemcel",
    "Marketed drug": "LENMELDY",
    "Modality": "Cell/Gene therapy",
    "Mechanism": "Ex vivo gene therapy for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ), or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD).",
    "Type": "Gene (ex vivo, autologous)",
    "Company": "Orchard Therapeutics (Europe) Limited",
    "Market ": "US/EMA",
    "DrugBank ID": "DB17538"
  },
  {
    "HGNCID": 10294,
    "Gene": "RPE65",
    "Condition/indication": "biallelic RPE65 mutation associated Leber congenital amaurosis",
    "Generic Name": "Voretigene neparvovec",
    "Marketed drug": "Luxturna",
    "Modality": "Gene therapy",
    "Mechanism": "Recombinant AAV2 delivers RPE65 to treat patients with RPE65-mutation-associated retinal dystrophy.",
    "Type": "In vivo AAV2",
    "Company": "Spark Therapeutics",
    "Market ": "US/EMA/Canada",
    "DrugBank ID": "DB13932"
  },
  {
    "HGNCID": 4827,
    "Gene": "HBB",
    "Condition/indication": "sickle cell disease",
    "Generic Name": "Lovotibeglogene autotemcel",
    "Marketed drug": "Lyfgenia",
    "Modality": "Cell/Gene therapy",
    "Mechanism": "Hematopoietic stem cells engineered with a lentivirus, BB305, expressing modified ßA-globin gene. Treats patients with certain kinds of sickle cell disease.",
    "Type": "Ex vivo Cell (autologous, modified)",
    "Company": "Bluebird Bio",
    "Market ": "US",
    "DrugBank ID": "DB18680"
  },
  {
    "Condition/indication": "The repair of single or multiple symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults",
    "Generic Name": "autologous cultured chondrocytes on porcine collagen membrane",
    "Marketed drug": "MACI",
    "Modality": "Cell therapy",
    "Mechanism": "Cellularized scaffold to repair cartilage defects of the knee. Matrix-applied characterised autologous cultured chondrocytes",
    "Type": "Cell (autologous, expanded)",
    "Company": "Vericel Corp.",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "vascular endothelial growth factor peripheral artery disease",
    "Generic Name": "Cambiogenplasmid",
    "Marketed drug": "Neovasculgen",
    "Company": "ArtGene Therapeutics",
    "Comment ": "not for rare disease"
  },
  {
    "Generic Name": "Omidubicel",
    "Marketed drug": "OMISIRGE",
    "Modality": "Cell therapy",
    "Mechanism": "Transplant of nicotinamide-modified HPCs from human cord blood.",
    "Type": "Cell (allogeneic, modified)",
    "Company": "Gamida Cell Ltd.",
    "Market ": "US",
    "DrugBank ID": "DB17132",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "Metastatic castrate-resistant hormone-refractory prostate cancer",
    "Generic Name": "Sipuleucel-T",
    "Marketed drug": "PROVENGE",
    "Modality": "Cell therapy",
    "Mechanism": "Antigen presenting cells are activated and used to treat certain types of prostate cancer. Sipuleucel-T / autologous dendritic cells",
    "Type": "Cell (autologous, activated/expanded) SCTMP",
    "Company": "Dendreon Corp.",
    "Market ": "US",
    "DrugBank ID": "DB06688",
    "Comment ": "not for rare disease"
  },
  {
    "Generic Name": "HPC, Cord Blood",
    "Marketed drug": "REGENECYTE ",
    "Modality": "Cell therapy",
    "Company": "StemCyte, Inc.",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "Pediatric patients with Congenital Athymia",
    "Generic Name": "Allogeneic processed thymus tissue",
    "Marketed drug": "RETHYMIC",
    "Modality": "Cell therapy",
    "Mechanism": "Thymus tissue implant to improve immune function in patients with certain types of congenital athymia. Human allogeneic processed thymus tissue-agdc",
    "Type": "Cell (allogeneic) TEP",
    "Company": "Enzyvant Therapeutics GmbH",
    "Market ": "US",
    "DrugBank ID": "DB16736",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 3546,
    "Gene": "F8",
    "Condition/indication": "hemophilia A",
    "Generic Name": "Valoctocogene roxaparvovec",
    "Marketed drug": "Roctavian",
    "Modality": "Gene therapy",
    "Mechanism": "Recombinant AAV5 delivers a B-domain deleted SQ form of F8 to treat patients with certain types of hemophilia A. ",
    "Company": "BioMarin International Limited",
    "Market ": "US/EMA",
    "DrugBank ID": "DB15561"
  },
  {
    "Condition/indication": "steroid-refractory acute graft-versus-host disease (SR-aGvHD)",
    "Generic Name": "Allogenic bone marrow-derived mesenchymal stem cells",
    "Marketed drug": "RYONCIL (remestemcel-L-rknd) ",
    "Modality": "Cell therapy",
    "Company": "Mesoblast, Inc.",
    "Market ": "US",
    "DrugBank ID": "DB18032",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 61,
    "Gene": "ABCD1",
    "Condition/indication": "cerebral adrenoleukodystrophy",
    "Generic Name": "Elivaldogene autotemcel",
    "Marketed drug": "Skysona",
    "Modality": "Gene therapy",
    "Mechanism": "Hematopoietic stem cells engineered with Lenti-D vectors that express the ABCD1 gene. Treats patients with a kind of cerebral adrenoleukodystrophy. Elivaldogene autotemcel / autologous CD34+ cells tranduced with retroviral vector containing The cDNA of the human ABCD1",
    "Type": "Ex vivo GTMP",
    "Company": "bluebird bio, Inc.",
    "Market ": "US",
    "DrugBank ID": "DB16746"
  },
  {
    "Condition/indication": "Symptomatic articular cartilage defects of the femoral condyle and the patella of the knee",
    "Generic Name": "Autologous cultured chondrocytes",
    "Marketed drug": "Spherox™",
    "Modality": "Cell therapy",
    "Mechanism": "Spheroids of human autologous matrix-associated chondrocytes",
    "Type": "SCTMP",
    "Company": "CO.DON Ag",
    "Market ": "US/EMA",
    "DrugBank ID": "DB10997",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "Adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated",
    "Generic Name": "Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen",
    "Marketed drug": "StrataGraft™",
    "Modality": "Cell therapy",
    "Mechanism": "Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Cellularized scaffold of keratinocytes and dermal fibroblasts in murine collagen to treat patients with some types of thermal burns.",
    "Type": "TEP",
    "Company": "Mallinckrodt plc",
    "Market ": "US",
    "DrugBank ID": "DB16709",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 186,
    "Gene": "ADA",
    "Condition/indication": "Severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)",
    "Generic Name": "Strimvelis",
    "Marketed drug": "Strimvelis™",
    "Modality": "Gene therapy",
    "Mechanism": "Autologous CD34+ cells transduced with a retroviral vector containing the ADA cDNA encoding human adenosine deaminase (ADA)",
    "Type": "Ex vivo GTMP",
    "Company": "Orchard Tx",
    "Market ": "EMA",
    "DrugBank ID": "DB17594"
  },
  {
    "Generic Name": "acellular tissue engineered vessel-tyod",
    "Marketed drug": "SYMVESS ",
    "Mechanism": "acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury ",
    "Company": "Humacyte Global, Inc.",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "Mantle Cell Lymphoma Acute Lymphoblastic Leukemia (ALL)",
    "Generic Name": "Brexucabtagene autoleucel",
    "Marketed drug": "Tecartus™",
    "Modality": "Cell therapy",
    "Mechanism": "Brexucabtagene autoleucel / autologous CAR T cells directed to CD19 ",
    "Type": "Ex vivo GTMP Cell (autologous, modified)",
    "Company": "Kite Pharma",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB15699",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "synovial sarcoma",
    "Generic Name": "Afamitresgene autoleucel",
    "Marketed drug": "Tecelra",
    "Type": "Ex vitro",
    "Company": "Adaptimmune",
    "Market ": "US",
    "DrugBank ID": "DB18592",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 2701,
    "Gene": "DCC",
    "Condition/indication": "Patients > 18 months with aromatic L-amino acid decarboxylase deficiencies",
    "Generic Name": "Eladocagene exuparvovec",
    "Marketed drug": "Upstaza™",
    "Mechanism": "Eladocagene exuparvovec / AAV2 vector containing the cDNA of human dopa decarboxylase (DCC)",
    "Type": "In vivo GTMP",
    "Company": "PTC Tx",
    "Market ": "US/EMA",
    "DrugBank ID": "DB16780"
  },
  {
    "HGNCID": 2214,
    "Gene": "COL7A1",
    "Condition/indication": "dystrophic epidermolysis bullosa (DEB)",
    "Generic Name": "Beremagene geperpavec",
    "Marketed drug": "Vyjuvek",
    "Modality": "Gene therapy",
    "Mechanism": "Recombinant HSV-1 delivers the collagen type VII gene (COL7) to treat certain wounds of patients with dystrophic epidermolysis bullosa with mutations in the COL7A1 gene.",
    "Type": "In vivo HSV-1",
    "Company": "Krystal Biotech",
    "Market ": "US",
    "DrugBank ID": "DB17831"
  },
  {
    "Condition/indication": "large B-cell lymphoma",
    "Generic Name": "Axicabtagene ciloleucel",
    "Marketed drug": "Yescarta",
    "Modality": "Cell therapy",
    "Mechanism": "CAR T cells engineered with gammaretrovirus to attack CD19-expressing tumor cells. Treats patients with certain kinds of relapsed or refractory large B-cell lymphoma.",
    "Type": "Ex vitro Cell (autologous, modified)",
    "Company": "Kite pharma",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB13915",
    "Comment ": "not for rare disease"
  },
  {
    "Condition/indication": "Add on treatment for patients who have received a haploidentical hematopoietic stem cell transplant",
    "Generic Name": "nalotimagene carmaleucel",
    "Marketed drug": "Zalmoxis™",
    "Mechanism": "Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)",
    "Type": "Ex vivo GTMP",
    "Company": "MolMed S.p.A.",
    "Market ": "Withdrawn",
    "Comment ": "not for rare disease"
  },
  {
    "HGNCID": 11117,
    "Gene": "SMN1",
    "Condition/indication": "spinal muscular atrophy type I",
    "Generic Name": "Onasemnogene abeparvovec",
    "Marketed drug": "Zolgensma",
    "Modality": "Gene therapy",
    "Mechanism": "Recombinant AAV9 delivers SMN1 to treat patients with certain types of spinal muscular atrophy. Onasemnogene abeparvovec / AAV9 vector containing the SMN1 transgene",
    "Type": "In vivo AAV9",
    "Company": "Novartis Gene Therapies",
    "Market ": "US/Canada/EMA",
    "DrugBank ID": "DB15528"
  },
  {
    "HGNCID": 4827,
    "Gene": "HBB",
    "Condition/indication": "Transfusion-dependent beta thalassemia",
    "Generic Name": "Betibeglogene autotemcel",
    "Marketed drug": "Zynteglo™",
    "Modality": "Cell/Gene therapy",
    "Mechanism": "Betibeglogene autotemcel / Lentiviral vector containing the cDNA of the human HBB gene. Hematopoietic stem cells engineered with a lentivirus, LentiGlobin BB305, to express HBB. Treats patients with certain types of ß-thalassemia.",
    "Type": "Ex vivo GTMP Cell (autologous, modified)",
    "Company": "Bluebird Bio",
    "Market ": "US",
    "DrugBank ID": "DB16900"
  }
]